US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-22 05:37:58 Source:opinionsViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Guardians ruin Francisco Lindor's Cleveland homecoming, trip Mets 3
Next:Georgia QB Jaden Rashada sues Florida coach, others over failed $14M NIL deal
You may also like
- Germany and Real Madrid great Toni Kroos to retire after Euro 2024
- China holds cultural and tourism event in L.A. following resumption of group tours
- Norway to add millions more to historic increase in defense spending announced last month
- Champions League is being expanded and EPL teams have failed to take advantage
- Massey, Perez hit homers to lead Royals in 8
- Theme park operator offers holiday treats
- EU announces 1 billion euros in aid for Lebanon amid a surge in irregular migration
- Reims coach Will Still leaves French league club with immediate effect
- Clark signs deal with Wilson Sporting Goods for signature line